Trials / Terminated
TerminatedNCT05179005
RibFix Advantage™ Post-Market Follow-Up
Zimmer Biomet Patient Outcome and Experience After Chest Wall Repair With RibFix Advantage™
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 1 (actual)
- Sponsor
- Zimmer Biomet · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To confirm safety, performance, and clinical benefits for the use of RibFix Advantage™ in the fixation, stabilization, and fusion of rib fractures and osteotomies of normal and osteoporotic bone
Detailed description
Retrospective review of subject demographic and hospital data with a prospective follow-up component evaluating clinical outcomes and quality of life for patients receiving RibFix Advantage for surgical stabilization of rib fractures from 2019 to 2021
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | RibFix Advantage | Intrathoracic rib fracture stabilization |
Timeline
- Start date
- 2023-04-20
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
- First posted
- 2022-01-05
- Last updated
- 2024-01-29
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05179005. Inclusion in this directory is not an endorsement.